<DOC>
	<DOC>NCT01351636</DOC>
	<brief_summary>The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.</brief_summary>
	<brief_title>Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Arotinolol</mesh_term>
	<criteria>Aged between 1875 yearsold; Chronic kidney disease stage 5 with haemodialysis treatment for 2 months; Patients with blood pressureâ‰¥140/90 mmHg after receiving 2 or 3 antihypertensive medications for 2 weeks; Patients who receiving alfa or beta blockers will be washed out for 2 weeks; Written informed consent Unstable angina, myocardial infarction, symptomatic or continuous arrhythmia, cardiosurgery in the last 2 months; Patients who taking class I antiarrhythmic drugs; Resting heart rate less than 60; Patients with systolic pressure less than 90 mmHg; Patients with chronic obstructive pulmonary disease and asthma; Patients with cerebral infarction in the last 2 weeks; Severe disorders of liver function; Allergy to the arotinolol; Patients who planning to have kidney transplantation in the near future; Pregnancy and breastfeeding; Malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>hypertension</keyword>
</DOC>